Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL441708 | 0.73 | — | — | |
| SCHEMBL6864380 | 0.70 | — | — | |
| SCHEMBL2975535 | 0.70 | — | — | |
| SCHEMBL3629397 | 0.70 | — | — | |
| Phosphonic Acid SCHEMBL124360 | 0.68 | — | — | |
| Phosphonic Acid SCHEMBL1168332 | 0.68 | — | — | |
| Phosphonic Acid SCHEMBL23674258 | 0.64 | — | — | |
| Phosphonic Acid SCHEMBL1167665 | 0.64 | — | — | |
| Phosphonic Acid SCHEMBL1204387 | 0.64 | — | — | |
| Phosphonic Acid SCHEMBL18422012 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 621 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9878984-B2 | Anti-cancer compounds | NORTHWESTERN UNIVERSITY (US) | 2018-01-30 | — | — | US | claimed |
| US-20140378503-A1 | ANTI-CANCER COMPOUNDS | NORTHWESTERN UNIVERSITY | 2014-12-25 | — | — | US | claimed |
| US-8829025-B2 | Anti-cancer compounds | NORTHWESTERN UNIVERSITY (US) | 2014-09-09 | — | — | US | claimed |
| US-20130225634-A1 | ANTI-CANCER COMPOUNDS | NORTHWESTERN UNIVERSITY (US) | 2013-08-29 | — | — | US | claimed |
| US-20100303719-A1 | ANTI-CANCER COMPOUNDS | NORTHWESTERN UNIVERSITY (US) | 2010-12-02 | — | — | US | claimed |
| US-20090275099-A1 | Methods and compositions for treating diseases and conditions associated with mitochondrial function | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-11-05 | — | — | US | claimed |
| WO-2009089537-A2 | ANTI-CANCER COMPOUNDS | NORTHWESTERN UNIVERSITY (US) | 2009-07-16 | — | — | WO | claimed |
| US-20260091104-A1 | NUCLEIC ACID VACCINES | MODERNATX, INC. (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4712948-A2 | GENE EDITING SYSTEMS AND COMPOSITIONS FOR TREATMENT OF HEMOGLOBINOPATHIES AND METHODS OF USING THE SAME | Renagade Therapeutics Management Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250312364-A1 | METHODS FOR THE USE OF PSYCHEDELICS | TRYP THERAPEUTICS INC. (CA) | 2025-10-09 | — | — | US | disclosed |
| US-12403177-B2 | Silk-based product formulations and methods of use | COCOON BIOTECH INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-12350375-B2 | Method for obtaining efficient viral vector-based compositions for vaccination or gene therapy | LEUKOCARE AG (DE) | 2025-07-08 | — | — | US | disclosed |
| WO-2025049959-A9 | GENE EDITING SYSTEMS, COMPOSITIONS, AND METHODS FOR TREATMENT OF VEXAS SYNDROME | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| WO-2000067802-A1 | FATTY ACID-N-SUBSTITUTED INDOL-3-GLYOXYL-AMIDE COMPOSITIONS AND USES THEREOF | PROTARGA, INC. (US) | 2000-11-16 | — | — | WO | disclosed |
| WO-2000053231-A2 | FATTY ACID-ANTICANCER CONJUGATES AND USES THEREOF | PROTARGA, INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| WO-1999036570-A2 | TRANSGLUTAMINASE LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE INC (US) | 1999-07-22 | — | — | WO | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0909183-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | Neuromedica, Inc. (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |